. intolerance). Ibrutinib is The existing gold normal therapy for people with relapsed/refractory disorder, determined by the effects of several section I-III trials, 115–119 but This is certainly also changing for two major causes: (i) an increasing proportion of patients at this time get ibrutinib as frontline therapy; and (ii) https://benitok319env6.blog2freedom.com/profile